Sanofi, BioN­Tech cut ear­ly-stage mR­NA can­cer ther­a­py from pipeline

Sanofi and BioN­Tech scrapped de­vel­op­ment of an mR­NA ther­a­py that can be in­ject­ed in­to a tu­mor af­ter see­ing re­sults from an in­ter­im analy­sis.

Sanofi on Fri­day dis­closed the de­vel­op­ment in its sec­ond quar­ter earn­ings re­port. The com­pa­nies first part­nered on a deal to de­vel­op can­cer im­munother­a­pies in 2015, and then in 2019, they put one can­di­date — SAR441000 — in a Phase I tri­al that en­rolled 77 pa­tients with ad­vanced sol­id tu­mors, clin­i­cal­tri­ shows. The com­pa­nies were test­ing the can­di­date as a monother­a­py and as a com­bi­na­tion treat­ment with Sanofi and Re­gen­eron’s PD-1 check­point in­hibitor Lib­tayo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.